Abstract
In a randomized controlled study of BCG in the treatment of stage Ib and II malignant melanoma, both the disease-free survival rate and the survival rate in the BCG treated group were significantly higher than those in the control group. The survival rate in the stage Ib patients of the BCG-treated group are significantly higher than the control group. The survival rates in patients aged less than 60 were significantly higher in the BCG treated group than in the control group. The survival rates in male patients were significantly higher than in the control group.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
